Adaptimmune to Participate in Two Bank Conferences This September
Adaptimmune to Participate in Two Bank Conferences This September
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September.
費城賓夕法尼亞和英國牛津,2024年8月28日 - Adaptimmune Therapeutics plc (NASDAQ: ADAP)是一家致力於重新定義實體腫瘤癌症治療的細胞療法公司,今天宣佈管理層將參加今年9月舉行的兩個投資銀行會議。
-
Wells Fargo Healthcare Conference, Boston, MA
- Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.
-
H.C. Wainwright 26th Annual Global Investment Conference, NYC, NY
- Fireside chat: Monday September 9, 2024, at 9:50 AM EDT.
- 富國銀行醫療保健會議,波士頓,馬薩諸塞州
- 座談會:2024年9月4日星期三,美國東部時間下午4:30。
- H.C. Wainwright第26屆全球投資大會,紐約,紐約州
- 座談會:2024年9月9日星期一,美國東部時間上午9:50。
The events will be webcast live and can be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at . Following the events, a replay of the presentation will be made available for a limited time.
這些活動將進行現場網絡直播,可以通過訪問Adaptimmune公司網站的「新聞中心」標籤下的「活動」以及「投資者與媒體」部分來查看。活動結束後,演示內容的重播將在有限的時間內提供。
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
關於Adaptimmune
Adaptimmune是一家完全一體化的細胞療法公司,致力於重新定義癌症的治療方式。憑藉其獨特的工程化T細胞受體(TCR)平台,公司正在開發個性化藥品,旨在針對難以治療的實體腫瘤癌症並顯著改善患者的癌症治療體驗。
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
前瞻性聲明
本發佈中包含根據1995年《私人證券訴訟改革法案》(PSLRA)的「前瞻性聲明」。這些前瞻性聲明涉及某些風險和不確定性。這種風險和不確定性可能會導致我們的實際結果與此類前瞻性聲明所示的結果不同,包括但不限於:我們的產品開發活動和臨床試驗的成功、成本和時間以及我們能否成功推進我們的TCR治療候選人通過監管和商業化流程。有關可能導致我們的實際結果與這些前瞻性聲明中所述的結果有所不同的風險和不確定性的進一步描述,以及與我們業務有關的風險,我們轉至《年報10-K》。提交給美國證券交易委員會的年度報告在2023年12月31日結束,我們提交的《10-Q》季度報告、《8-K》現狀報告和向美國證券交易委員會提供的其他文件。本新聞發佈中包含的前瞻性聲明僅適用於聲明發表的日期,我們不承擔任何更新此類前瞻性聲明以反映隨後發生的事件或情況的義務。
Adaptimmune Contact
Adaptimmune聯繫方式
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
投資者關係
Juli P. Miller博士-企業事務和投資者關係副總裁
電話:+1 215 825 9310
手機:+1 215 460 8920
電子郵件:Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
媒體關係
Dana Lynch,企業傳播高級總監
手機:+1 267 990 1217
電子郵件:Dana.Lynch@adaptimmune.com